Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Fernández, Marta Llauradó, DiMattia, Gabriel E, Dawson, Amy, Bamford, Sylvia, Anderson, Shawn, Hennessy, Bryan T, Anglesio, Michael S, Shepherd, Trevor G, Salamanca, Clara, Hoenisch, Josh, Tinker, Anna, Huntsman, David G, Carey, Mark S
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/
https://ncbi.nlm.nih.gov/pubmed/27822414
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados